Merck KGaA posts strong first-half results

4 August 2022

German life sciences and pharma firm Merck KGaA today posted financial results for first-half 2022, showing that net sales increased by 14.3% compared with the second quarter of 2021 to 5,568 million euros ($5.64 billion).

All business sectors contributed to the strong organic sales increase of 6.6%, especially the “Big 3” growth drivers of Merck: Process Solutions and Life Science Services in Life Science, new Healthcare products as well as Semiconductor Solutions in Electronics.

Earnings before interest, taxes, depreciation and amortization (EBITDA) pre, the most important financial indicator used to steer operating business, rose by 13.1% to 1,782 million. Earnings per share pre improved by 17.9% to 2.64 euros.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK